In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Please provide your email address to receive an email when new articles are posted on . “Ulcerative colitis is a chronic inflammatory disease of the colon that can significantly affect a patient’s ...
Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and ...
1 st and only once-daily combination containing the active ingredient of TOPROL-XL ® (metoprolol succinate) ER tablets plus low-dose hydrochlorothiazide, offers the dual efficacy of a beta blocker and ...
Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...
Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health regulator for its generic amphetamine extended-release tablets indicated ...
A widely-used diabetes drug has been recalled after manufacturers found it contained unacceptably high levels of a cancer-causing contaminant. Indian pharmaceutical company Marksans Pharma Limited is ...
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved XELJANZ ® XR extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results